June 2022 Endocrine Month in Review

1. Tirzepatide (Mounjaro) Now Available in US Pharmacies, Ushering in New Era of Glucose-Lowering
   Eli Lilly and Company announced tirzepatide (Mounjaro) is now available in US pharmacies. We sat down with SURPASS-2 principal investigator Juan Frias, MD, at ADA 2022 and got his perspective on the potential of tirzepatide and what hesitancies clinicians may have related to the prescription of the dual GIP/GLP-1 receptor agonist.
2. Time to Rethink Metformin as First-Line Therapy? Perspective from ADA 2022
   After new data from the Diabetes Prevention Program Outcomes Study suggested neither metformin nor lifestyle intervention addressed the cardiovascular risk in patients with prediabetes, we asked experts at ADA 2022 if it was time to rethink metformin as first-line therapy in type 2 diabetes.
3. Diabetes Dialogue at ADA 2022
   In addition to an ADA 2022 overview from hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, special edition episodes tackle CGM uptake in primary care, addressing and reducing barriers to care, and perspective on the meeting from a certified diabetes educator.
4. Semaglutide 2.4 mg Reduces Long-Term Type 2 Diabetes Risk
   W. Timothy Garvey, MD, discusses the results of a study leveraging data from STEP 1 and STEP 4 to determine the reduction in 10-year risk of type 2 diabetes seen with use of semaglutide 2.4 mg vs placebo therapy.
5. SURMOUNT-1: Tirzepatide Provides Significant, Sustained Weight Loss in Obesity
   Full data from SURMOUNT-1 was presented at ADA 2022 and demonstrated tirzepatide in 5 mg, 10 mg, or 15 mg doses provides superior weight loss compared to placebo therapy, with this weight loss maintained throughout the duration of the trial.
6. Long COVID Could Be a Major Issue Looming Over Diabetes Community
   New research from a review assessing the risk of long COVID in patients with diabetes suggests the risk of developing long COVID in these patients could be more than 4-fold greater than the risk among patients without diabetes.